Form 8-A12B - Registration of securities [Section 12(b)]
2023年7月22日 - 2:39AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-A
FOR REGISTRATION OF
CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION
12(b) OR 12(g) OF THE
SECURITIES EXCHANGE
ACT OF 1934
AEON Biopharma, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
85-3940478 |
(State of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
5 Park Plaza, Suite 1750
Irvine, California |
92614 |
(Address of principal executive offices) |
(Zip Code) |
Securities to be registered pursuant to Section
12(b) of the Act:
Title for each class
to be so registered |
Name of each exchange on which
each class is to be registered |
|
|
Class A Common Stock, par value $0.0001 per share |
New York Stock Exchange American |
|
|
Warrants, each whole warrant exercisable to purchase one share of Class A Common
Stock at an exercise price of $11.50 per share |
New York Stock Exchange American |
If this form relates to the registration of a class of securities pursuant
to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. x
If this form relates to the registration of a class of securities pursuant
to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. ¨
Securities Act registration statement file number to which this form
relates: 333-252310; 333-269006 (if applicable)
Securities to be registered pursuant to Section 12(g) of the Act: N/A
Explanatory Note
This
Registration Statement on Form 8-A is being filed by AEON Biopharma, Inc. (the “Company”), formerly known as Priveterra
Acquisition Corp., with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the transfer of the
listing of the Company’s Class A common stock, par value $0.0001 per share (“Company Common Stock”), and its
warrants to purchase shares of Company Common Stock (the “Company Warrants”) from The Nasdaq Stock Market LLC to the
NYSE American LLC.
Item 1. Description of Registrant’s
Securities to be Registered.
The
securities to be registered hereby are the Company Common Stock and Company Warrants.
The
description of the Company Common Stock and Company Warrants registered hereunder is set forth under the caption “Description
of New AEON’s Securities After the Business Combination” in the Company’s definitive proxy statement/prospectus,
dated as of May
12, 2023 (File No. 333-269006) and filed with the SEC on May 12, 2023 (including any subsequent supplements or amendments with
respect to the description of the Company Common Stock and Company Warrants), and is incorporated herein by reference.
Item 2. Exhibits.
In
accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of
this registration statement because no other securities of the registrant are registered on The Nasdaq Stock Market LLC and the securities
registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant
to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to
be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 21,
2023
|
AEON Biopharma, Inc. |
|
|
|
|
By: |
/s/ Marc Forth |
|
|
Name: |
Marc Forth |
|
|
Title: |
Chief Executive Officer |
Priveterra Acquisition C... (NASDAQ:PMGMU)
過去 株価チャート
から 4 2024 まで 5 2024
Priveterra Acquisition C... (NASDAQ:PMGMU)
過去 株価チャート
から 5 2023 まで 5 2024